Skip to main content

When it comes to retail, we're in a barbell economy, Jim Cramer told his Mad Money viewers Thursday. Both low-end and high-end retailers are thriving, but everything in the middle continues to decline.

Many investors are still shying away from the likes of Dollar Tree (DLTR) - Get Free Report and Dollar General (DG) - Get Free Report , fearing that increased tariffs will crimp these companies' profits. But in reality, these are fabulous operators, Cramer said, and Dollar General in particular has the best revenue growth around. Other discounters like Costco (COST) - Get Free Report , Walmart (WMT) - Get Free Report and Target (TGT) - Get Free Report also continue to thrive.

At the high end, we have retailers like RH (RH) - Get Free Report which soared 15.8% solid on a beat-and-raise quarter. RH has a fabulous stock buyback that has retired a staggering 60% of its float in just three years. Lululemon Athletica (LULU) - Get Free Report has also been on fire, forecasting low double-digit same store sales growth.

The only part of retail that's not working are the department stores, Cramer concluded, where even Macy's (M) - Get Free Report turnaround plans haven't seemed to attract customers.

On Real Money, Jim Cramer takes a closer look at the retailers for the haves and the have-nots. Get more of his insights with a free trial subscription to Real Money.

Plant-Based Burger Wars 

With Tyson Foods (TSN) - Get Free Report preparing to challenge Beyond Meat (BYND) - Get Free Report in the plant-based burger wars, where should investors place their bets? Cramer weighed in with his opinion.

Cramer said he's a big admirer of what Beyond Meat has been able to accomplish. The company spent 10 years perfecting its burger alternatives and they're almost indistinguishable from the real thing. The stock, however, is now in the stratosphere and that has him worried.

Tyson on the other hand as a proven track record as a packaged foods company. But Tyson also inexplicably sold its stake in Beyond Meat before its IPO, which made Cramer question the company's commitment to the category. The company is also using genetically modified ingredients in its plant-based offerings, something they may offend younger consumers who shun GMOs.

In the end, Cramer said, the market is big enough to support both companies, but he's not a fan of either stock at the moment. 

Cramer and the AAP team have updates on two portfolio names: Disney (DIS) - Get Free Report and Viacom (VIAB) - Get Free Report . Find out what they're telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts Plus

Executive Decision: Dexcom

For his "Executive Decision" segment, Cramer spoke with Kevin Sayer, chairman, president and CEO of Dexcom (DXCM) - Get Free Report , the glucose monitoring company.

Sayer said Dexcom is working closely with a number of partners, including Medtronic (MDT) - Get Free Report to create an artificial pancreas than can both monitor glucose levels, then use smart algorithms to deliver the insulin patients need when they need it. Combined, these tools are making diabetes care easier and ultimately leading to better outcomes for diabetes patients.

When asked what's coming next, Sayer said they always have something in the works including upgrades to their existing G6 platform, direct connections to the Apple (AAPL) - Get Free Report Watch as well as their next generation G7 platform.

Sayer was bullish on the Philippines, where Dexcom recently opened a call center. He said the country has a lot of workers that really understand the healthcare industry and are eager to work.

Turning to the topic of growth, Sayer said Dexcom still has a lot of growth ahead of it, especially internationally. 

Battle of the Analysts

When analysts disagree, investors get to see the best of both worlds, Cramer reminded viewer. Today's case study: Capri Holdings (CPRI) - Get Free Report , the parent company of Michael Kors, Jimmy Choo and Versace.

Shares of Capri have been cut in half over the past 12 months, as the company's posted lackluster results as a combined entity. The original Michael Kors purchased Jimmy Choo in 2017, then less than a year later made what some saw as a pricey bid for Versace. The integration of the three luxury brands came right at the top of the retail cycle, leading to shares falling to just seven times earnings.

Capri's management has a plan to turn around their ailing brands and whether you're a bull or a bear on the stock depends on whether you believe in management's plan. The bearish analysts are non-believers, saying the turnaround will take time and management is being too optimistic. The bulls are believers, citing the company's conservative cost-cutting targets.

Cramer said given the low share price, he's siding with the bulls. He said the risk/reward makes this an attractive investment and he thinks management can attain at least most of their targets. 

Life Science Opportunities

The life science stocks have been red-hot lately, and while some of that strength has stemmed from market rotations, Cramer said most of the more is coming from solid execution. He recommended ThermoFisher Scientific (TMO) - Get Free Report and Danaher (DHR) - Get Free Report as two names that can be bought right now.

ThermoFisher is a great long-term investment, Cramer said. Shares are up 27% for the year and unlike other healthcare stocks, this company is not likely to become a political football. The company is actively shedding low-margin business and moving into more specialized biopharma businesses, all of which are helping to bolster the bottom line.

As for Danaher, this is another well-run company that has an excellent track record of making smart acquisitions to turn good businesses into great ones. Shares are up 35% for the year.

Finally, Cramer told viewers to check out Avantor (AVTR) - Get Free Report , the newly-minted chemical company that supplies the life science industry. He said this stock has also been on fire and is a buy into any weakness. 

Lightning Round

In the Lightning Round, Cramer was bullish on Synopsys (SNPS) - Get Free Report , Home Depot (HD) - Get Free Report , Neogenomics (NEO) - Get Free Report , Charles River Labs (CRL) - Get Free Report and Ball Corp (BLL) - Get Free Report .

Cramer was bearish on Mercer International  (MERC) - Get Free Report , Lumentum Holdings (LITE) - Get Free Report , Olin (OLN) - Get Free Report and CommScope (COMM) - Get Free Report

Introducing TheStreet Courses: Financial titans Jim Cramer and Robert Powell are bringing their market savvy and investing strategies to you. Learn how to create tax-efficient income, avoid top mistakes, reduce risk and more. With our courses, you will have the tools and knowledge needed to achieve your financial goals. Learn more about TheStreet Courses on investing and personal finance here.

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

Advice from Jim Cramer: Setting Up A Portfolio For Your Grandchildren

At the time of publication, Cramer's Action Alerts PLUS had a position in DIS, VIAB, HD, AAPL.